Key Takeaways DexCom received a warning letter from the Food and Drug Administration following inspections of two of its ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

The U.S. Department of Agriculture has dissolved two key food safety advisory committees, sparking concern over government ...

The S&P 500 Index ($SPX) (SPY) today is down -1.94%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.75%, and the ...

Stock futures and bond yields fell early on Monday after President Trump did not rule out the possibility that his policies would cause a recession and data showed deflationary pressures building in ...

S&P 500 E-Mini futures (ESH25) are down -0.90%, and March Nasdaq 100 E-Mini futures (NQH25) are down -1.04% this morning, while Treasury yields also fell, as concerns about the health of the U.S.

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

Baird Medical Investment Holdings Ltd. ("Baird Medical" or the "Company"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical ...